BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Marisi G, Petracci E, Raimondi F, Faloppi L, Foschi FG, Lauletta G, Iavarone M, Canale M, Valgiusti M, Neri LM, Ulivi P, Orsi G, Rovesti G, Vukotic R, Conti F, Cucchetti A, Ercolani G, Andrikou K, Cascinu S, Scartozzi M, Casadei-Gardini A. ANGPT2 and NOS3 Polymorphisms and Clinical Outcome in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib. Cancers (Basel) 2019;11:E1023. [PMID: 31330833 DOI: 10.3390/cancers11071023] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Azuma S, Uojima H, Chuma M, Shao X, Hidaka H, Nakazawa T, Kondo M, Numata K, Iwabuchi S, Kako M, Maeda S, Koizumi W, Atsuda K. Influence of NOS3 rs2070744 genotypes on hepatocellular carcinoma patients treated with lenvatinib. Sci Rep 2020;10:17054. [PMID: 33051476 DOI: 10.1038/s41598-020-73930-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Dal Bo M, De Mattia E, Baboci L, Mezzalira S, Cecchin E, Assaraf YG, Toffoli G. New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma. Drug Resistance Updates 2020;51:100702. [DOI: 10.1016/j.drup.2020.100702] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 6.5] [Reference Citation Analysis]
3 Caputo F, Dadduzio V, Tovoli F, Bertolini G, Cabibbo G, Cerma K, Vivaldi C, Faloppi L, Rizzato MD, Piscaglia F, Celsa C, Fornaro L, Marisi G, Conti F, Silvestris N, Silletta M, Lonardi S, Granito A, Stornello C, Massa V, Astara G, Delcuratolo S, Cascinu S, Scartozzi M, Casadei-Gardini A. The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib. PLoS One 2020;15:e0232449. [PMID: 32379785 DOI: 10.1371/journal.pone.0232449] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 11.0] [Reference Citation Analysis]
4 Butkiewicz D, Gdowicz-Kłosok A, Krześniak M, Rutkowski T, Krzywon A, Cortez AJ, Domińczyk I, Składowski K. Association of Genetic Variants in ANGPT/TEK and VEGF/VEGFR with Progression and Survival in Head and Neck Squamous Cell Carcinoma Treated with Radiotherapy or Radiochemotherapy. Cancers (Basel) 2020;12:E1506. [PMID: 32526933 DOI: 10.3390/cancers12061506] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
5 Vanderborght B, Lefere S, Vlierberghe HV, Devisscher L. The Angiopoietin/Tie2 Pathway in Hepatocellular Carcinoma. Cells 2020;9:E2382. [PMID: 33143149 DOI: 10.3390/cells9112382] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
6 Brunetti O, Gnoni A, Licchetta A, Longo V, Calabrese A, Argentiero A, Delcuratolo S, Solimando AG, Casadei-Gardini A, Silvestris N. Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib. Medicina (Kaunas) 2019;55:E707. [PMID: 31640191 DOI: 10.3390/medicina55100707] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 8.7] [Reference Citation Analysis]
7 Schipilliti FM, Garajová I, Rovesti G, Balsano R, Piacentini F, Dominici M, Gelsomino F. The Growing Skyline of Advanced Hepatocellular Carcinoma Treatment: A Review. Pharmaceuticals (Basel) 2021;14:43. [PMID: 33429973 DOI: 10.3390/ph14010043] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
8 Song S, Bai M, Li X, Gong S, Yang W, Lei C, Tian H, Si M, Hao X, Guo T. Early Predictive Value of Circulating Biomarkers for Sorafenib in Advanced Hepatocellular Carcinoma. Expert Rev Mol Diagn 2022. [PMID: 35234564 DOI: 10.1080/14737159.2022.2049248] [Reference Citation Analysis]
9 Bai J, Liu Z, Liu J, Zhang S, Tian Y, Zhang Y, Ren L, Kong D. Mitochondrial metabolic study guided by proteomics analysis in hepatocellular carcinoma cells surviving long-term incubation with the highest dose of sorafenib. Aging (Albany NY) 2019;11:12452-75. [PMID: 31881007 DOI: 10.18632/aging.102582] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
10 Omar HH, Nasef SI, Anani MM. The Association of Angiopoietin-2 1064 C/T Rs3020221 Gene Polymorphism with Knee Osteoarthritis. Immunol Invest 2022;:1-13. [PMID: 35384768 DOI: 10.1080/08820139.2022.2058404] [Reference Citation Analysis]
11 Gonçalves DA, Jasiulionis MG, Melo FHM. The Role of the BH4 Cofactor in Nitric Oxide Synthase Activity and Cancer Progression: Two Sides of the Same Coin. Int J Mol Sci 2021;22:9546. [PMID: 34502450 DOI: 10.3390/ijms22179546] [Reference Citation Analysis]
12 Atwa SM, Odenthal M, M El Tayebi H. Genetic Heterogeneity, Therapeutic Hurdle Confronting Sorafenib and Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. Cancers (Basel) 2021;13:4343. [PMID: 34503153 DOI: 10.3390/cancers13174343] [Reference Citation Analysis]
13 Wang H, Rao B, Lou J, Li J, Liu Z, Li A, Cui G, Ren Z, Yu Z. The Function of the HGF/c-Met Axis in Hepatocellular Carcinoma. Front Cell Dev Biol 2020;8:55. [PMID: 32117981 DOI: 10.3389/fcell.2020.00055] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 12.0] [Reference Citation Analysis]
14 Gao K, Zhu Y, Wang H, Gong X, Yue Z, Lv A, Zhou X. Network pharmacology reveals the potential mechanism of Baiying Qinghou decoction in treating laryngeal squamous cell carcinoma. Aging (Albany NY) 2021;13:26003-21. [PMID: 34986125 DOI: 10.18632/aging.203786] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Lai E, Astara G, Ziranu P, Pretta A, Migliari M, Dubois M, Donisi C, Mariani S, Liscia N, Impera V, Persano M, Tolu S, Balconi F, Pinna G, Spanu D, Pireddu A, Saba G, Camera S, Musio F, Puzzoni M, Pusceddu V, Madeddu C, Casadei Gardini A, Scartozzi M. Introducing immunotherapy for advanced hepatocellular carcinoma patients: Too early or too fast? Crit Rev Oncol Hematol. 2021;157:103167. [PMID: 33271389 DOI: 10.1016/j.critrevonc.2020.103167] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
16 Donisi C, Puzzoni M, Ziranu P, Lai E, Mariani S, Saba G, Impera V, Dubois M, Persano M, Migliari M, Pretta A, Liscia N, Astara G, Scartozzi M. Immune Checkpoint Inhibitors in the Treatment of HCC. Front Oncol 2020;10:601240. [PMID: 33585218 DOI: 10.3389/fonc.2020.601240] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
17 Li H, Han G, Li X, Li B, Wu B, Jin H, Wu L, Wang W. MAPK-RAP1A Signaling Enriched in Hepatocellular Carcinoma Is Associated With Favorable Tumor-Infiltrating Immune Cells and Clinical Prognosis. Front Oncol 2021;11:649980. [PMID: 34178637 DOI: 10.3389/fonc.2021.649980] [Reference Citation Analysis]
18 Choi GH, Jang ES, Kim JW, Jeong SH. Prognostic role of plasma level of angiopoietin-1, angiopoietin-2, and vascular endothelial growth factor in hepatocellular carcinoma. World J Gastroenterol 2021; 27(27): 4453-4467 [PMID: 34366616 DOI: 10.3748/wjg.v27.i27.4453] [Reference Citation Analysis]
19 Marin JJG, Serrano MA, Monte MJ, Sanchez-Martin A, Temprano AG, Briz O, Romero MR. Role of Genetic Variations in the Hepatic Handling of Drugs. Int J Mol Sci 2020;21:E2884. [PMID: 32326111 DOI: 10.3390/ijms21082884] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]